Prognostic and Therapeutic Significance of BTN3A Proteins in Tumors

被引：19
作者：
Chen, Sihan [1 ,2 ]
Li, Zhangyun [1 ]
Huang, Wenyi [1 ]
Wang, Yanyan [3 ]
Fan, Shaohua [1 ]
机构：
[1] Jiangsu Normal Univ, Sch Life Sci, Xuzhou 221116, Jiangsu, Peoples R China
[2] Jiangsu Normal Univ, Coll Hlth Sci, Xuzhou, Jiangsu, Peoples R China
[3] Xuzhou First Peoples Hosp, Dept Ultrason Med, Xuzhou 221000, Jiangsu, Peoples R China
来源：
JOURNAL OF CANCER | 2021年 / 12卷 / 15期
关键词：
Butyrophilin; 3A; Tumor; Prognosis; DELTA-T-CELLS; PRENYL PYROPHOSPHATE STIMULATION; BUTYROPHILIN GENE FAMILY; MILK-FAT; ACTIVATION; 3A1; IMMUNOTHERAPY; MOLECULES; PHOSPHOANTIGENS; LYMPHOCYTES;
D O I：
10.7150/jca.57831
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The Butyrophilin 3A (BTN3A) family is a type I transmembrane protein belonging to the immunoglobulin (Ig) superfamily. The family contains three members: BTN3A1, BTN3A2 and BTN3A3, which share 95% homology in the extracellular domain. The expression of BTN3A family members is different in different types of tumors, which plays an important role in tumor prognosis. Among them, there are many studies on tumor immunity of BTN3A1, which shows that it is essential for the activation of V gamma 9V delta 2 T cells, while BTN3A3 is expected to become a potential therapeutic target for breast cancer. Recent studies have shown that the BTN3A family is closely related to the occurrence and development of tumors. Now the BTN3A family has become one of the research hotspots and is expected to become new tumor prediction and treatment targets.
引用
收藏
页码：4505 / 4512
页数：8
相关论文
共 69 条
[1]   Human gamma delta T cells: Evolution and ligand recognition [J].
Adams, Erin J. ;
Gu, Siyi ;
Luoma, Adrienne M. .
CELLULAR IMMUNOLOGY, 2015, 296 (01) :31-40
[2]   Evolutionary and polymorphism analyses reveal the central role of BTN3A2 in the concerted evolution of the BTN3 gene family [J].
Afrache, Hassnae ;
Pontarotti, Pierre ;
Abi-Rached, Laurent ;
Olive, Daniel .
IMMUNOGENETICS, 2017, 69 (06) :379-390
[3]   The butyrophilin (BTN) gene family: from milk fat to the regulation of the immune response [J].
Afrache, Hassnae ;
Gouret, Philippe ;
Ainouche, Shanaiz ;
Pontarotti, Pierre ;
Olive, Daniel .
IMMUNOGENETICS, 2012, 64 (11) :781-794
[4]   Immune modulation by butyrophilins [J].
Arnett, Heather A. ;
Viney, Joanne L. .
NATURE REVIEWS IMMUNOLOGY, 2014, 14 (08) :559-569
[5]   BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC) [J].
Benyamine, Audrey ;
Loncle, Celine ;
Foucher, Etienne ;
Blazquez, Juan-Luis ;
Castanier, Celine ;
Chretien, Anne-Sophie ;
Modesti, Mauro ;
Secq, Veronique ;
Chouaib, Salem ;
Gironella, Meritxell ;
Vila-Navarro, Elena ;
Montalto, Giuseppe ;
Dagorn, Jean-Charles ;
Dusetti, Nelson ;
Iovanna, Juan ;
Olive, Daniel .
ONCOIMMUNOLOGY, 2018, 7 (01)
[6]   BTN3A molecules considerably improve V9V2T cells-based immunotherapy in acute myeloid leukemia [J].
Benyamine, Audrey ;
Le Roy, Aude ;
Mamessier, Emilie ;
Gertner-Dardenne, Julie ;
Castanier, Celine ;
Orlanducci, Florence ;
Pouyet, Laurent ;
Goubard, Armelle ;
Collette, Yves ;
Vey, Norbert ;
Scotet, Emmanuel ;
Castellano, Remy ;
Olive, Daniel .
ONCOIMMUNOLOGY, 2016, 5 (10)
[7]   Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma [J].
Bian, Benjamin ;
Fanale, Daniele ;
Dusetti, Nelson ;
Roque, Julie ;
Pastor, Sonia ;
Chretien, Anne-Sophie ;
Incorvaia, Lorena ;
Russo, Antonio ;
Olive, Daniel ;
Lovanna, Juan .
ONCOIMMUNOLOGY, 2019, 8 (04)
[8]   New Insights Into the Regulation of γδ T Cells by BTN3A and Other BTN/BTNL in Tumor Immunity [J].
Blazquez, Juan-Luis ;
Benyamine, Audrey ;
Pasero, Christine ;
Olive, Daniel .
FRONTIERS IN IMMUNOLOGY, 2018, 9
[9]   BTN3A2 serves as a prognostic marker and favors immune infiltration in triple-negative breast cancer [J].
Cai, Peian ;
Lu, Zhenhui ;
Wu, Jianjun ;
Qin, Xiong ;
Wang, Zetao ;
Zhang, Zhi ;
Zheng, Li ;
Zhao, Jinmin .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2020, 121 (03) :2643-2654
[10]  
Cavaletto M, 2002, PROTEOMICS, V2, P850, DOI 10.1002/1615-9861(200207)2:7<850::AID-PROT850>3.0.CO
1234567